Home > Oncology > ESMO 2021 > Breast Cancer > Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy

Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy

Presented By
Prof. Valentina Guarneri, University of Padua, Italy
Conference
ESMO 2021
Survival data from 4 randomised studies of the tyrosine kinase inhibitor lapatinib in combination with neoadjuvant trastuzumab versus trastuzumab (plus anthracycline or paclitaxel chemotherapy) in patients with HER2-positive early breast cancer showed that patients who achieved a pathological complete response (pCR) had a reduced risk of relapse by 65% in patients with hormone receptor-negative tumours and by 40% in patients with hormone receptor-positive disease. The optimal selection of patients with HER2-positive early breast cancer who may benefit most from de-escalation of treatment remains an unmet need. Prof. Valentina Guarneri (University of Padua, Italy) pointed out that although all studies reported improved outcomes if patients achieved pCR, survival data were not conclusive in any of the individual studies [1]. To address this gap, Prof. Guarneri and colleagues performed a meta-analysis of 4 randomised phase 2 and 3 studies (CALGB40601 [2], CH...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on